Abstract
Albendazole has broad-spectrum coverage as an antiparasitic drug, and the reported side effects have been minimal. We report the case of a patient with febrile neutropenia beginning during the second week of therapy for a hepatic, splenic and peritoneal echinococcal cyst. This case was a 49-year-old man who presented with a large cystic abdominal mass. His medical history was significant for non-cirrhotic portal hypertension and recurrent cholangitis. Albendazole sulfoxide peak dose and half-life are significantly prolonged by liver disease and concomitant administration of certain drugs. The severity and duration of albendazole-induced neutropenia in this case was likely related to the underlying liver disease. Frequent serial monitoring of blood counts and cessation of medication with any evidence of marrow toxicity in such patients are warranted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
